reports
Travere Therapeutics to Present at Upcoming Investor Conferences
Travere Therapeutics to Present at Upcoming Investor Conferences SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will participate in the following upcoming investor conferences: BofA Securities Health Care Conference Wednesday, May 15, 2024, at 8:00 a.m. PT Jefferies Global Healthcare ConferenceWednesday, June 5, 2024, at 3:00 p.m. ET Live webcasts of the presentations will be accessible on the Investor page of Travere’s website at ir.travere.com/events-presentations. Replays will be available for up to 30 da...
Cytokinetics Reports First Quarter 2024 Financial Results
Cytokinetics Reports First Quarter 2024 Financial Results Primary Results and Two Additional Analyses from SEQUOIA-HCM to be Presented in a Late-Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress Opened Enrollment to CEDAR-HCM, a Clinical Trial of Aficamtenin a Pediatric Population with Obstructive HCM Announced Topline Data from the Phase 1 Study of CK-586;Phase 2 Clinical Trial to Begin in Q4 2024 SOUTH SAN FRANCISCO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) reported financial results for the fir...
Intra-Cellular Therapies to Participate in Two Upcoming Investor Confe...
Intra-Cellular Therapies to Participate in Two Upcoming Investor Conferences NEW YORK, May 08, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will participate in two upcoming investor conferences: 2024 RBC Capital Markets Global Healthcare ConferenceTuesday, May 14, 2024 at 10:00 a.m. ET in New York, NY Bank of America Healthcare Conference 2024Thursday, May 16, 2024 at 9:20 a.m. PT (12:20 p.m. ET) in La...
Cytokinetics Announces Start of CEDAR-HCM, a Clinical Trial of Aficam...
Cytokinetics Announces Start of CEDAR-HCM, a Clinical Trial of Aficamten in a Pediatric Population With Symptomatic Obstructive Hypertrophic Cardiomyopathy SOUTH SAN FRANCISCO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that CEDAR-HCM (Clinical Evaluation of Dosing with Aficamten to Reduce Obstruction in a Pediatric Population in HCM), a clinical trial of aficamten in a pediatric population with symptomatic obstructive hypertrophic cardiomyopathy (HCM), is open to enrollment. Aficamten is a next-in-class cardiac myosin inhibitor in ...
Cytokinetics Announces Topline Data From Phase 1 Clinical Study of CK-...
Cytokinetics Announces Topline Data From Phase 1 Clinical Study of CK-4021586 Data Support Advancement to Phase 2 Clinical Trial in Patients with Heart Failure with Preserved Ejection Fraction Expected to Begin in Q4 2024 Full Data from the Phase 1 Study to be Presented at a Medical Congress in 2H 2024 SOUTH SAN FRANCISCO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced topline data from the Phase 1 study of CK-4021586 (CK-586). The study met its primary and secondary objectives to assess the safety, tolerability and pharmacokinetic...
- David Carlson
- David Nierengarten
- Dennis Pak
- Martin Fan
Krystal Biotech to Present at BofA Securities 2024 Health Care Confere...
Krystal Biotech to Present at BofA Securities 2024 Health Care Conference PITTSBURGH, May 08, 2024 (GLOBE NEWSWIRE) -- . (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in the BofA Securities 2024 Health Care Conference on May 14, 2024, in Las Vegas. Krish S. Krishnan, Chairman and Chief Executive Officer, will take part in a fireside chat scheduled at 2:20 pm PT and host investor meetings throughout the day. A webcast of the presentation will be available beginning at 2:20 pm PT on Tuesday, May 14, 2024 and wil...
Beam Therapeutics to Participate in RBC Capital Markets 2024 Global He...
Beam Therapeutics to Participate in RBC Capital Markets 2024 Global Healthcare Conference CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer of Beam, plans to participate in a fireside chat during the RBC Capital Markets 2024 Global Healthcare Conference on Wednesday, May 15, 2024, at 1:35 p.m. ET in New York City. A live webcast will be available in the investor section of the company's website at , and will be archived for 60 day...
- Wedbush Research
GEO GEO GROUP INC. (THE)
LOGN LOGITECH INTERNATIONAL S.A.
WAL WESTERN ALLIANCE BANCORP
SBUX STARBUCKS CORPORATION
RHP RYMAN HOSPITALITY PROPERTIES INC.
PEB PEBBLEBROOK HOTEL TRUST
GPRO GOPRO INC. CLASS A
FIS FIDELITY NATIONAL INFORMATION SERVICES INC.
EXLS EXLSERVICE HOLDINGS INC.
EWBC EAST WEST BANCORP INC.
CXW CORECIVIC INC.
CTMX CYTOMX THERAPEUTICS INC.
OSTK OVERSTOCK.COM INC.
HST HOST HOTELS & RESORTS INC.
7974 NINTENDO CO. LTD.
EA ELECTRONIC ARTS INC.
PK PARK HOTELS & RESORTS INC.
CELH CELSIUS HOLDINGS INC.
DNLI DENALI THERAPEUTICS INC
HEAR TURTLE BEACH CORP.
PRPL PURPLE INNOVATION
ARVN ARVINAS HOLDING
LYFT LYFT
GOSS GOSSAMER BIO
RVLV REVOLVE GROUP
IDYA IDEAYA BIOSCIENCES
CRSR CORSAIR GAMING
REAL REALCO
UPST UPSTART HOLDINGS
TWKS THOUGHTWORKS HOLDING
MQ MARQETA INC
JANX JANUX THERAPEUTICS INC
YOU CLEAR SECURE INC
VIGL VIGIL NEUROSCIENCE INC
HR HEALTHCARE TRUST OF AMERICA INC.
BROS DUTCH BROS INC
- Laura Chico
- Laura Chico
- Moshe Katri
- Spencer Lebov
Y-mAbs Reports First Quarter 2024 Financial Results and Recent Corpora...
Y-mAbs Reports First Quarter 2024 Financial Results and Recent Corporate Developments Reported U.S. DANYELZA® net product revenues of $18.6 million for the first quarter of 2024, representing a YoY increase of 11% Reported Worldwide DANYELZA net product revenues of $19.4 million for the first quarter of 2024, representing a 4% YoY decrease due to international volumesCash and cash equivalents of $75.7 million as of March 31, 2024, and cash burn of only $2.9 million for the quarter ended March 31, 2024 Management reiterates full year 2024 financial guidance and anticipated cash runway into 2...
Myriad Genetics Reports Strong First Quarter 2024 Financial Results; A...
Myriad Genetics Reports Strong First Quarter 2024 Financial Results; Achieves 12% Revenue Growth Year-Over-Year; Significantly Improved Year-Over-Year Net Loss and Generated Positive Adjusted EBITDA Highlights: First quarter revenue of $202 million grew 12% year-over-year, driven by Prenatal (22%), Pharmacogenomics (21%), and Hereditary Cancer (16%). First quarter average revenue per test improved by 2% over the prior year period, reflecting no-pay reduction efforts.First quarter GAAP net loss of $26 million and positive adjusted EBITDA of $4 million; net loss and adjusted EBITDA improve...
Denali Therapeutics Reports First Quarter 2024 Financial Results and B...
Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases, today reported financial results for the first quarter ended March 31, 2024, and provided business highlights. "It has been an impactful first quarter, and we are excited about multiple opportu...
Cytokinetics to Hold Annual Meeting of Stockholders
Cytokinetics to Hold Annual Meeting of Stockholders SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that its Annual Meeting of Stockholders will be held on Wednesday, May 15, 2024 at 10:00 AM Pacific Time at the Company’s headquarters, 350 Oyster Point Blvd., South San Francisco, CA. Immediately after the conclusion of the Annual Meeting of Stockholders, Robert I. Blum, President and Chief Executive Officer, is scheduled to present an overview of Cytokinetics’ performance. Stockholders of record at the close of busin...
Myriad Genetics Announces Reorganization of European Operations and Sa...
Myriad Genetics Announces Reorganization of European Operations and Sale of EndoPredict Business SALT LAKE CITY, May 07, 2024 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the reorganization of its European operations to better align company resources to its domestic opportunities while continuing to serve key biopharma partners and patients outside the United States. As part of the reorganization, Myriad signed a definitive agreement to sell its EndoPredict® business to Eurobio Scientific, a leading French group in in vitro med...
Intra-Cellular Therapies Reports First Quarter 2024 Financial Results
Intra-Cellular Therapies Reports First Quarter 2024 Financial Results CAPLYTA Q1 2024 net product sales were $144.8 million, compared to $94.7 million for the same period in 2023, representing a 53% increase CAPLYTA’s strong prescription uptake continues: Q1 2024 CAPLYTA total prescriptions increased 39%, versus the same period in 2023 CAPLYTA 2024 net product sales guidance reiterated at $645 - $675 million Announced robust positive Phase 3 results from Study 501 evaluating lumateperone as an adjunctive therapy to antidepressants in patients with major depressive disorder (MDD) ...
Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Fina...
Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results Dosing Completed for Sentinel Cohort of BEACON Phase 1/2 Trial of BEAM-101 in Severe Sickle Cell Disease; Expansion Cohort Initiated Clinical Trial Authorisation (CTA) Application Cleared for the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency; Study to Initiate in First Half of 2024 BEAM-301 On Track for Submission of U.S. Investigational New Drug (IND) Application in First Half of 2024 Ended First Quarter 2024 with $1.1 Billion in Cash, Cash Equivalents and Marketable Securities; Cash Runw...
- David Carlson
- David Nierengarten
- Dennis Pak
- Martin Fan
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.